Back to Search Start Over

Porous silicon-cell penetrating peptide hybrid nanocarrier for intracellular delivery of oligonucleotides.

Authors :
Rytkönen J
Arukuusk P
Xu W
Kurrikoff K
Langel U
Lehto VP
Närvänen A
Source :
Molecular pharmaceutics [Mol Pharm] 2014 Feb 03; Vol. 11 (2), pp. 382-90. Date of Electronic Publication: 2013 Dec 30.
Publication Year :
2014

Abstract

The largest obstacle to the use of oligonucleotides as therapeutic agents is the delivery of these large and negatively charged biomolecules through cell membranes into intracellular space. Mesoporous silicon (PSi) is widely recognized as a potential material for drug delivery purposes due to its several beneficial features like large surface area and pore volume, high loading capacity, biocompatibility, and biodegradability. In the present study, PSi nanoparticles stabilized by thermal oxidation or thermal carbonization and subsequently modified by grafting aminosilanes on the surface are utilized as an oligonucleotide carrier. Splice correcting oligonucleotides (SCOs), a model oligonucleotide drug, were loaded into the positively charged PSi nanoparticles with a loading degree as high as 14.3% (w/w). Rapid loading was achieved by electrostatic interactions, with the loading efficiencies reaching 100% within 5 min. The nanoparticles were shown to deliver and release SCOs, in its biologically active form, inside cells when formulated together with cell penetrating peptides (CPP). The biological effect was monitored with splice correction assay and confocal microscopy utilizing HeLa pLuc 705 cells. Furthermore, the use of PSi carrier platform in oligonucleotide delivery did not reduce the cell viability. Additionally, the SCO-CPP complexes formed in the pores of the carrier were stabilized against proteolytic digestion. The advantageous properties of protecting and releasing the cargo and the possibility to further functionalize the carrier surface make the hybrid nanoparticles a potential system for oligonucleotide delivery.

Details

Language :
English
ISSN :
1543-8392
Volume :
11
Issue :
2
Database :
MEDLINE
Journal :
Molecular pharmaceutics
Publication Type :
Academic Journal
Accession number :
24341621
Full Text :
https://doi.org/10.1021/mp4002624